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Allograft rejection is induced by graft tissue infiltration of alloreactive T cells that are 
activated mainly in secondary lymphoid organs of the host. DOCK2 plays a critical role in 
lymphocyte homing and immunological synapse formation by regulating the actin cytoskeleton, 
yet its role in the in vivo immune response remains unknown. We show here that DOCK2 
deficiency enables long-term survival of cardiac allografts across a complete mismatch of 
the major histocompatibility complex molecules. In DOCK2-deficient mice, alloreactivity and 
allocytotoxicity were suppressed significantly even after in vivo priming with alloantigens, 
which resulted in reduced intragraft expression of effector molecules, such as interferon-
 
 
 
, 
granzyme B, and perforin. This is mediated, at least in part, by preventing potentially alloreactive 
T cells from recruiting into secondary lymphoid organs. In addition, we found that DOCK2 is 
critical for CD28-mediated Rac activation and is required for the full activation of alloreactive 
T cells. Although DOCK2-deficient, alloreactive T cells were activated in vitro in the presence 
of exogenous interleukin-2, these T cells, when transferred adoptively, failed to infiltrate 
into the allografts that were transplanted into RAG1-deficient mice. Thus, DOCK2 deficiency 
attenuates allograft rejection by simultaneously suppressing multiple and key processes. We 
propose that DOCK2 could be a novel molecular target for controlling transplant rejection.
 
Graft tissue infiltration of activated T cells is a
hallmark of cellular rejection of allografts (1).
This process involves a complex cascade of
molecular interactions and cellular responses,
including the chemokine-dependent migra-
tion of T cells, the recognition by TCRs of
allopeptides bound to MHC molecules, the
engagement of costimulation and adhesion
molecules with their ligands, and the activation
of multiple intracellular signal transduction
pathways which lead to the release of cytokines
that are key to T cell expansion and graft tissue
destruction (2–6). Thus far, targeting of TCR
signaling pathways successfully controlled al-
lograft rejection in clinical and experimental
transplantation (5, 7). More recently, several
attempts have been made to block chemokine–
chemokine receptor interactions and costimula-
tory molecules for controlling transplant rejec-
tion (8–14). However, because migration and
activation of T cells are critically dependent on
remodeling of the actin cytoskeleton (15, 16),
inhibition of the cytoskeletal reorganization in
T cells is an alternative approach to attenuating
allograft rejection.
Rac
 
 
 
is one of the Rho family GTPases that
are known to regulate membrane polarization
and cytoskeletal dynamics in various cells (17).
Rac is composed of three isoforms: Rac1, Rac2,
and Rac3. Rac1 is expressed ubiquitously and
Rac3 is expressed highly in the brain, whereas
Rac2 is restricted largely to hematopoietic cells.
The critical role of Rac activation in cell mi-
gration has been well established (15, 18). In
addition, the activation of Rac has been im-
plicated in immunological synapse formation, a
large-scale molecular movement at the interface
between T cells and APCs, which is considered
to be critical for sustained T cell activation (16,
19–21). Therefore, Rac activation would be a
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target for manipulating T cell migration and activation.
However, the ubiquitous expression and redundancy of Rac
isoforms preclude using Rac as a molecular target for con-
trolling transplant rejection.
CDM family proteins, 
 
Caenorhabditis elegans
 
 CED-5, hu-
man DOCK180, and 
 
Drosophila melanogaster
 
 Myoblast City,
are known to regulate the actin cytoskeleton by functioning
upstream of Rac (22). DOCK2 is a new member of the
CDM family and is expressed predominantly in lymphocytes
(23). With the use of DOCK2-deficient (DOCK2
 
 
 
/
 
 
 
) mice,
we reported that DOCK2 is essential for chemokine- and
antigen-induced Rac activation in T cells by functioning
downstream of chemokine receptors and TCRs (23, 24).
DOCK2
 
 
 
/
 
 
 
 mice exhibit a migration defect of T cells in re-
sponse to various chemokines in vitro (23). In addition, we
found that antigen-induced translocation of TCR and lipid
rafts to the APC interface is impaired severely in DOCK2
 
 
 
/
 
 
 
T cells, and results in a substantial reduction of alloreactivity
in MLR (24). However, the effect of DOCK2 deficiency on
T cell migration and activation in an in vivo situation (e.g.,
transplant rejection) has not been determined.
This issue was addressed in the present study by per-
forming cardiac transplantation between BALB/c mice
and C57BL/6J (B6) mice, a strain combination that is
considered to have a strong histocompatibility difference,
with or without DOCK2 expression. Here, we provide
evidence that DOCK2 deficiency in the recipients en-
ables long-term survival of cardiac allografts by suppress-
ing priming and activation of naive T cells in secondary
lymphoid organs, and by attenuating graft tissue infiltra-
tion of activated T cells.
 
RESULTS
DOCK2 deficiency enables long-term survival 
of cardiac allografts
 
To assess the effect of DOCK2 deficiency on allograft re-
jection, we performed cardiac transplantation between
BALB/c mice and B6 mice with or without DOCK2 ex-
pression. The cardiac grafts from B6 mice survived in B6
recipients for 
 
 
 
100 d with no sign of rejection (Table I).
When BALB/c hearts were transplanted into WT B6 or
DOCK2
 
 
 
/
 
 
 
 (heterozygote control) mice, the allografts
 
Table I.
 
DOCK2 deficiency prolongs survival of cardiac allografts
 
Group Drug Period
 
n
 
Survival days (
 
n
 
)
 
a
 
MST p-value
 
B6
 
→
 
B6
 
  
 
5 69, 
 
 
 
100 (4)
 
 
 
100
BALB/c
 
→
 
B6
 
  
 
5 7, 8, 11 (2), 13 11
BALB/c
 
→
 
DOCK2
 
   
 
  
 
7 7 (4), 8 (3)  7 NS
 
b
 
BALB/c
 
→
 
DOCK2
 
   
 
  
 
7 14, 20, 34, 60, 80, 90, 
 
 
 
100 60
 
 
 
0.01
 
c
 
BALB/c
 
→
 
RAG1
 
   
 
  
 
5 95, 96, 
 
 
 
100 (3)
 
 
 
100
 
 
 
0.01
BALB/c
 
→
 
B6 Tac
 
d
 
Day 1–10 5 9, 10, 13, 15, 26 13 NS
BALB/c
 
→
 
DOCK2
 
   
 
Tac Day 1–10 6 43, 84, 
 
 
 
100 (4)
 
 
 
100
 
 
 
0.01
 
a
 
The numeral in the parentheses is the number of mice surviving to that day.
 
b
 
No significance versus the corresponding WT B6 allograft control. 
 
c
 
P 
 
 
 
 0.01 versus the corresponding WT B6 allograft control.
 
d
 
Tacrolimus 3.2 mg/kg/d for 10 d after transplantation.
Figure 1. Histology shows no evidence of acute rejection in the 
allografts from DOCK2    recipients. (A) BALB/c heart tissues were 
harvested from WT B6, DOCK2 /  with or without Tac treatment, and 
RAG1 /  recipients on day 6 after transplantation and were stained 
with hematoxylin and eosin. (B) Tissue sections of BALB/c cardiac 
grafts that survived 80 or 123 d in DOCK2 /  recipients were stained 
with hematoxylin and eosin. (C) DOCK2 /  recipient mice that were 
treated with a brief course of low-dose Tac were killed on day 108 or 
304 after transplantation, and BALB/c heart tissues were stained with 
hematoxylin and eosin. 
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were rejected with a median survival time (MST) of 11
and 7 d, respectively. However, BALB/c cardiac allografts
survived in DOCK2
 
 
 
/
 
 
 
 mice for a median of 60 d, in-
cluding one case with graft survival for more than 100 d,
although this MST did not reach the level of RAG1
 
 
 
/
 
 
 
mice that lack all T and B cells (MST 
 
 
 
100 d).
Treatment of DOCK2
 
 
 
/
 
 
 
 recipient mice with a brief
course of low-dose tacrolimus (Tac), a calcineurin inhibitor,
resulted in a strong synergistic effect. 10 d of therapy with Tac
(3.2 mg/kg/d) prolonged cardiac allograft survival by only 2 d
in the WT B6 recipients, but induced long-term engraftment
in four of the six DOCK2
 
 
 
/
 
 
 
 recipient mice (Table I). These
results indicate that DOCK2 deficiency effectively attenuates
cardiac allograft rejection, and enables permanent graft survival
when combined with certain medication. Conversely, we
found no prolongation of cardiac allograft survival when
DOCK2
 
 
 
/
 
 
 
 mice were used as donors (unpublished data).
 
DOCK2 deficiency improves myocardial histopathology 
of allografts
 
We then compared the histopathology of the allografts har-
vested on day 6 after transplantation. The classic signs of
acute rejection were seen in the allografts from the WT B6
and DOCK2
 
 
 
/
 
 
 
 controls, including strong interstitial infil-
tration of mononuclear cells—especially concentrated in the
perivascular and epicardial regions—with severe hemor-
rhage, edema, and necrosis (Fig. 1 A and not depicted). In
contrast, the allografts from DOCK2
 
 
 
/
 
 
 
 recipient mice and
from RAG1
 
 
 
/
 
 
 
 mice, irrespective of Tac treatment, showed
only mild interstitial mononuclear cell infiltration with little
evidence of hemorrhage, edema, and necrosis (Fig. 1 A).
Histologic evaluation at later time points revealed certain ev-
idences of acute rejection, including mononuclear cell infil-
tration and focal edema, in the allografts surviving 
 
 
 
80 d af-
ter transplantation into DOCK2
 
 
 
/
 
 
 
 recipients (Fig. 1 B, left).
However, the allograft surviving 
 
 
 
100 d in a DOCK2
 
 
 
/
 
 
 
recipient showed well-preserved myocardial structure and
normal vessels with no interstitial fibrosis (Fig. 1 B, right).
Similarly, no signs of rejection were found in the allograft
that was harvested on day 108 after transplantation from a
DOCK2
 
 
 
/
 
 
 
 recipient that was treated with a brief course of
low-dose Tac (Fig. 1 C, left). In one Tac-treated DOCK2
 
 
 
/
 
 
 
recipient, the allograft survived 
 
 
 
300 d. Although the al-
lograft that was harvested from this recipient on day 304 after
Figure 2. T cell infiltration into and T cell activation in cardiac 
allografts are reduced in DOCK2    recipients. BALB/c heart tissues 
that were harvested from the WT B6 and DOCK2 /  recipients with or 
without Tac treatment on day 6 after transplantation were stained with 
antibody against CD3  (A), CD25 (C), and CD68 (E). As a control, B6 heart 
tissues that were harvested from B6 mice were analyzed similarly. The 
numbers of infiltrating CD3  (B), CD25  (D), and CD68  (F) cells were 
analyzed in a semi-quantitative manner. Data are mean   SEM of at 
least six separate B6 grafts from B6 mice (white bar), and those of BALB/c 
grafts from the WT B6 (black bar) and DOCK2 /  recipients, with (light 
gray bar) and without (dark gray bar) Tac treatment. *P   0.05 comparison 
between WT B6 and DOCK2 /  recipients with or without Tac treatment. 
(G–I) The intragraft infiltration of CD3  (G), CD25  (H), and CD68  (I) 
cells were compared between DOCK2 /  mice (dark gray bar) and those 
that were treated with Tac (light gray bar) on days 15 and 30 after 
transplantation of BALB/c hearts. 
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transplantation exhibited mild to moderate interstitial infil-
tration of mononuclear cells and fibrosis (Fig. 1 C, right),
these results provide further evidence that DOCK2 defi-
ciency effectively attenuates cardiac allograft rejection.
 
DOCK2 deficiency attenuates graft tissue infiltration 
of T cells
 
To better understand the mechanism by which DOCK2 de-
ficiency attenuates allograft rejection, we first analyzed the
number of infiltrating cells bearing CD3, CD25, or CD68
macrophage marker in the cardiac grafts on day 6 after trans-
plantation. Whereas cells expressing CD3, CD25, or CD68
macrophage marker were scarce in the B6 grafts transplanted
into B6 mice, BALB/c grafts from the WT B6 recipients ex-
hibited infiltration of numerous mononuclear cells express-
ing these cell surface markers (Fig. 2, A, C, and E). How-
ever, the number of CD3
 
 
 
 T cells in the allografts of
DOCK2
 
 
 
/
 
 
 
 recipient mice with or without Tac treatment
decreased to 40% or 56%, on average, of the WT B6 level
(Fig. 2 B). In addition, the allografts in DOCK2
 
 
 
/
 
 
 
 mice, ir-
respective of Tac treatment, showed significantly
 
 
 
reduced
CD25
 
 
 
 cells (Fig. 2 D). Conversely, the numbers of CD68
 
 
 
macrophages (Fig. 2 F) and NK cells (not depicted) infiltrat-
ing into the allografts were unchanged between WT B6 and
DOCK2 /  mice with or without Tac treatment. When
similar analysis was performed on days 15 and 30 after trans-
plantation, no significant difference could be found in the
number and the composition of the infiltrating cells between
DOCK2 /  recipients and those that were treated with Tac
(Fig. 2, G–I).
DOCK2 deficiency attenuates intragraft expression of T cell 
effector molecules
We then examined the intragraft expression of cytokines,
chemokines, and cytolytic factors on day 6 after transplanta-
tion using real-time quantitative RT-PCR. Whereas the ex-
pression of cytokines (IL-2, IFN- , TNF- ), chemokines
(regulated upon activation, normal T cell expressed and se-
creted [RANTES]), and cytolytic molecules (granzyme B,
perforin) was scarcely detected in the B6 grafts that were
transplanted into B6 mice, BALB/c grafts from the WT B6
recipient mice exhibited strong induction of all effector mol-
Figure 3. The gene expression profile of cytokines and cytolytic 
factors is altered in the allografts from DOCK2    recipients. BALB/c 
heart grafts harvested from WT B6 (black bar), DOCK2 /  (dark gray bar), 
and Tac-treated DOCK2 /  recipients (light gray bar) on day 6 after 
transplantation were used for measurement of IL-2, TNF- , RANTES, IFN- , 
granzyme B, and perforin mRNA expression by real time RT-PCR. As a control, 
B6 grafts from B6 mice were analyzed similarly (white bar). Data are 
expressed relative to GAPDH level and represent mean   SEM of three 
animals per group. *P   0.05 comparison between WT B6 and DOCK2 /  
recipients with or without Tac treatment.
Figure 4. Alloreactivity and allocytotoxicity are suppressed in 
DOCK2    recipients. (A) Splenic T cells were prepared from WT B6 (black 
bar), DOCK2 /  (dark gray bar), and Tac-treated DOCK2 /  (light gray bar) 
recipients on day 6, 15, or 30 after transplantation of BALB/c hearts, and 
were cultured with mitomycin C–treated spleen cells of B6, BALB/c, or C3H 
mice. Data are shown as mean   SEM of the stimulation index calculated 
by dividing the responses to BALB/c or C3H spleen cells by that to B6 
spleen cells. *P   0.05 comparison between WT B6 and DOCK2 /  
recipients with or without Tac treatment. #P   0.05 comparison be-
tween DOCK2 /  recipients and those treated with Tac. (B) Splenic T cells 
were prepared from WT B6 (black bar), DOCK2 /  (dark gray bar), and 
Tac-treated DOCK2 /  (light gray bar) recipients on day 6, 15, or 30 after 
transplantation of BALB/c hearts as effector cells, and were cultured with 
Con A–stimulated BALB/c or C3H spleen cells as target cells. Data are shown 
as mean   SEM of the percentage of cytotoxicity of triplicate wells. 
*P   0.05 comparison between WT B6 and DOCK2 /  recipients with or 
without Tac treatment. #P   0.05 comparison between DOCK2 /  recipients 
and those treated with Tac.JEM VOL. 202, October 17, 2005 1125
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ecules tested (Fig. 3). Even when DOCK2 /  mice were
used as recipients, with or without Tac treatment, the ex-
pression of IL-2, TNF- , and RANTES was induced com-
parably in the allografts (Fig. 3). However, the expression of
IFN- , granzyme B, and perforin was reduced significantly
in the allografts from DOCK2 /  recipient mice, irrespec-
tive of Tac treatment (Fig. 3). The expression of all effector
molecules tested was unchanged between DOCK2 /  re-
cipients and those treated with Tac, not only on day 6, but
also on days 15 and 30 after transplantation (Fig. 3). These
results indicate that DOCK2 deficiency effectively attenuates
the expression of multiple T cell effector molecules.
DOCK2 deficiency attenuates alloreactivity 
or allocytotoxicity
Having found that the number of activated T cells and the
expression of their effector molecules were reduced in the
allografts from DOCK2 /  recipient mice, we compared
the MLR and the CTL activity among WT B6 and
DOCK2 /  mice, with or without Tac treatment, on day 6
after transplantation of BALB/c heart grafts. Splenic T cells
from WT B6 recipients showed a vigorous proliferative re-
sponse to the mitomycin C–treated BALB/c spleen cells,
which was considerably greater than that of the third-party
control, C3H spleen cells (Fig. 4 A). In the case of splenic T
cells from DOCK2 /  mice, however, the proliferative re-
sponse was reduced to 40% of the WT level (Fig. 4 A). The
more profound suppression of the MLR was found when
splenic T cells from DOCK2 /  mice treated with a low
dose of Tac for 10 d were used as responders (Fig. 4 A).
Splenic T cells from Tac-treated DOCK2 /  mice also had
significantly less proliferative response than that of the un-
treated DOCK2 /  mice on day 15, but not day 30, after
transplantation (Fig. 4 A); this indicated that Tac treatment
has an additional effect on suppressing the proliferative re-
sponse of alloreactive T cells. Consistent with the alloreac-
tivity results, splenic T cells from DOCK2 /  recipients, ir-
respective of Tac treatment, revealed weak allocytotoxicity
against donor antigen (Fig. 4 B). Taken together, these re-
sults indicate that the T cell response to allo-MHC mole-
cules is impaired significantly in DOCK2 /  mice, even af-
ter in vivo priming with alloantigens.
We then examined whether exogenous IL-2 restores the
proliferative response of DOCK2 /  T cells in the MLR.
Consistent with the results shown in Fig. 4 A, DOCK2 / 
T cells harvested on day 15 after transplantation showed
poor proliferative response to BALB/c spleen cells in the ab-
sence of exogenous IL-2 (Fig. 5 A). However, the prolifera-
tive responses of DOCK2 /  T cells were enhanced by add-
ing IL-2 to the culture (Fig. 5 A), which suggested that some
of the alloreactive T cells are in the anergic state in
DOCK2 /  recipients. This led us to explore whether
DOCK2 functions downstream of CD28, a costimulatory
molecule that is required for the full activation of T cells.
When DOCK2 /  T cells were stimulated with anti-CD28
mAb, GTP-bound, activated Rac was detected readily (Fig.
5 B). However, such Rac activation was totally abolished
in DOCK2 /  T cells (Fig. 5 B), which indicated that
DOCK2 also is critical for Rac activation in CD28-medi-
ated costimulation of T cells.
DOCK2    naive T cells transferred into RAG1    mice 
exhibit poor proliferative response and fail to infiltrate 
into the allograft tissues
To visualize the effect of DOCK2 deficiency on activa-
tion and migration of lymphocytes in vivo, naive lym-
phocytes from B6 and DOCK2 /  mice were labeled
with 5,6-carboxyfluorescein diacetate succinimidyl ester
(CFSE), and adoptively transferred into RAG1 /  recipi-
ents with B6 or BALB/c heart grafts. On day 6 after
transfer of 60   106 lymphocytes, more than 80% of B6 T
cells recovered from RAG1 /  recipients were CFSE-
negative, irrespective of the origin of the cardiac grafts
(Fig. 6 A); this indicated that B6 T cells undergo homeo-
stasis-driven proliferation. However, under the same con-
ditions,   40% of the DOCK2 /  T cells remained
CFSE-bright, undivided cells, even after transfer into
RAG1 /  recipients having BALB/c cardiac grafts (Fig. 6
A). It is known that competition limits the extent of ho-
meostatic proliferation. When 6 or 3   106 CFSE-labeled
DOCK2 /  lymphocytes were transferred into RAG1 / 
mice, the percentage of undivided cells was reduced to
Figure 5. DOCK2 functions downstream of CD28 and is required 
for full T cell activation. (A) Splenic T cells were prepared from DOCK2 /  
recipients on day 15 after transplantation of BALB/c hearts, and were 
stimulated with mitomycin C–treated spleen cells of B6 mice (white bar) 
or BALB/c mice in the absence (black bar) or presence (light gray bar) of 
exogenous IL-2. As a control, splenic T cells from naive B6 mice were 
analyzed similarly. Data are shown as mean   SEM of 3H-thymidine 
incorporation of triplicate wells. (B) Splenic T cells of DOCK2 /  and 
DOCK2 /  mice were stimulated with anti-CD28 mAb for the indicated 
times. Cell extracts were incubated with glutathione S-transferase–fusion 
(GST)-PAK1–Rac binding domain, and the activated and total Rac were 
analyzed by immunoblot using anti-Rac mAb.DOCK2-DEFICIENCY SUPPRESSES TRANSPLANT REJECTION | Jiang et al. 1126
1.2% or 0.3%, respectively (Fig. 6 B and not depicted).
Taken together, these results suggest that DOCK2 defi-
ciency does not abolish, but reduces the susceptibility to,
homeostatic proliferation.
We then compared T cell infiltration into B6 or
BALB/c cardiac grafts on day 6 after adoptive transfer of
60   106 lymphocytes, by staining the graft tissue sections
with anti-CD3 mAb. Whereas B6 T cells were scarcely
detected in B6 cardiac grafts, considerable numbers of B6
T cells infiltrated into BALB/c heart grafts (Fig. 6, C and
D); this indicated that alloreactivity is required for graft
tissue infiltration of T cells. In contrast to the results on
B6 T cells, DOCK2 /  T cells failed to infiltrate into the
BALB/c heart grafts (Fig. 6, C and D).
DOCK2 deficiency affects graft tissue infiltration 
of activated, alloreactive T cells
To examine whether DOCK2 deficiency affects graft tis-
sue infiltration of activated, alloreactive T cells, T cells
from B6 and DOCK2 /  mice were stimulated with the
mitomycin C–treated BALB/c spleen cells in vitro in the
presence of exogenous IL-2, and were adoptively trans-
ferred into RAG1 /  recipients with BALB/c heart grafts.
Functional and flow cytometric analysis confirmed that T
cells from both strains were comparably activated under
this condition (unpublished data). On day 6 after adoptive
transfer of B6 T cells, numerous CD3  T cells were found
in BALB/c cardiac grafts (Fig. 7, A and B). However, CD3 
T cells infiltrating into the allografts were scarcely de-
tected in the case of DOCK2 /  T cells (Fig. 7, A and B).
These results indicate that DOCK2 deficiency attenuates
graft tissue infiltration of T cells, even when the priming
defect is bypassed.
DISCUSSION
T lymphocyte migration and activation are important for
initiating allograft rejection and are critically dependent on
remodeling of the actin cytoskeleton (15, 16). Therefore,
Figure 6. DOCK2    naive T cells transferred into RAG1    mice 
exhibit poor proliferative response and fail to infiltrate into the 
allograft tissues. (A) CFSE-labeled naive lymphocytes (60  106) from 
B6 or DOCK2 /  mice were adoptively transferred into RAG1 /  mice 
transplanted with B6 hearts (left panel) or BALB/c hearts (middle and right 
panels). On day 6 after transfer, CFSE intensity was analyzed for all CD3  
T cell populations of the spleen. The percentages of CFSE  cells (M2) and 
CFSE  undivided cells (M1) are shown. (B) CFSE-labeled naive lymphocytes 
(6   106) from B6 (left panel) or DOCK2 /  (right panel) mice were adoptively 
transferred into RAG1 /  mice, and CFSE intensity was analyzed for all 
CD3  T cell populations of the spleen on day 6 after transfer. The percentages 
of CFSE  (M2) cells and CFSE  undivided cells (M1) are shown. 
(C and D) CFSE-labeled naive lymphocytes (60   106) from B6 or DOCK2 /  
mice were adoptively transferred into RAG1 /  mice transplanted with B6 
hearts (left panel) or BALB/c hearts (middle and right panels). On day 6 after 
transfer, graft tissues were stained with anti-CD3  mAb (C), and the numbers 
of infiltrating T cells were analyzed in a semi-quantitative manner (D). 
Data are mean   SEM of the number of CD3  cells in at least three mice 
per group. White bar, B6 T cell infiltration into B6 heart tissues; black bar, 
B6 T cell infiltration into BALB/c heart tissues; dark gray bar; DOCK2 /  
T cell infiltration into BALB/c heart tissues. *P   0.05 comparison between 
WT B6 and DOCK2 /  T cell infiltration into BALB/c hearts.JEM VOL. 202, October 17, 2005 1127
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provided that remodeling of the actin cytoskeleton could be
manipulated in lymphocytes, such manipulation would be a
useful approach to attenuate allograft rejection. In the
present study, we have provided evidence that DOCK2, a
regulator of the actin cytoskeleton in lymphocytes, could be
a novel molecular target for controlling transplant rejection.
DOCK2 deficiency enabled significant prolongation of
cardiac allograft survival across a complete mismatch of
MHC with an MST of 60 d when compared with the MSTs
of 11 d in the WT B6 and 7 d in the DOCK2 /  controls.
Myocardial histopathology revealed that the classic signs of
acute rejection were seen in the allografts from the WT B6
controls, but not in the allografts from the DOCK2 /  re-
cipients on day 6 after transplantation. This histologic feature
of DOCK2 /  recipients was similar to that of allografts
from RAG1 /  recipient mice, lacking all T and B cells, un-
der the same conditions. Although there is a need to pin-
point the sources of the variation in the allograft survival
times and the exact causes of eventual loss of allografts in
some DOCK2 /  recipients, these results indicate that
DOCK2 deficiency effectively attenuates allograft rejection.
The expression of IFN- , granzyme B, and perforin, all
of which are known to be involved in the induction of cyto-
toxicity and direct damage of allograft tissues (25–28), was
reduced significantly in the allografts from DOCK2 /  re-
cipients. Considering that allografts normally are rejected,
even in IL-2 / , IFN-  / , or perforin /  mice (29–31), it
is unlikely that the decreased expression of IFN- , granzyme
B, or perforin alone contributes to survival of the cardiac al-
lografts in DOCK2 /  recipients. Therefore, the combined
reduction of these effector molecules or the changes in gene
expression profiling might be responsible for prevention of
allograft rejection in this transplant setting. Alternatively,
DOCK2 deficiency might attenuate the expression of some
other undetermined molecules that are critical for graft re-
jection. Nonetheless, together with the evidence of the de-
creased number of CD25  cells in the allografts, these results
suggest that DOCK2 deficiency affects the activation of al-
loreactive T cells, and leads to allograft survival.
Because cardiac allograft survival is prolonged remark-
ably in mice lacking LNs, Peyer’s patches, and spleen (32–
34), activation of alloreactive T cells is considered to occur
mainly in secondary lymphoid organs. We reported that
DOCK2 deficiency severely impairs the chemotactic re-
sponses of naive lymphocytes to homeostatic chemokines,
such as CCL19 (EBI1-ligand chemokine), CCL21 (second-
ary lymphoid tissue chemokine), and CXCL13 (B-lympho-
cyte chemoattractant) (23). Consistent with this report,
homing of adoptively transferred DOCK2 /  lymphocytes
to peripheral LNs, mesenteric LNs, Peyer’s patches, and
white pulp of the spleen is reduced remarkably, compared
with that of WT lymphocytes (35). Therefore, it is suggested
that DOCK2 deficiency attenuates alloreactivity, at least in
part, by reducing the number of potentially alloreactive T
cells in secondary lymphoid organs. Recently, Beckmann et
al. (36) reported that the deficiency of CCR7, a receptor for
CCL19 and CCL21, has only a modest effect on cardiac al-
lograft survival. Different from the case of CCR7 (37),
DOCK2 functions downstream of various, if not all,
chemokine receptors and critically regulates T cell homing,
T cell egress from the thymus, and B cell homing (23, 35).
This might account, in part, for the differential effect on car-
diac allograft survival between DOCK2 /  and CCR7 / 
mice. However, because of its nature to regulate the actin
cytoskeleton, DOCK2 deficiency is expected to have addi-
tional effects on suppression of T cell activation.
We found that splenic T cells from DOCK2 /  recip-
ients showed significantly lower MLR response and CTL
activity toward donor antigens than those of the WT B6
controls. Because the proliferative response of DOCK2 / 
T cells in the MLR was much enhanced in the presence
of exogenous IL-2, it seems likely that in DOCK2 /  re-
cipients, some of the alloreactive T cells are in the anergic
state. Thus far, costimulatory molecules, such as CD80/
CD86 and CD28, have been the major targets for block-
ing T cell full activation and inducing allograft tolerance
(11–14). Although the nature of costimulation is not un-
derstood fully, it was reported that delivering the signal
that induces lipid raft clustering in T cells is related to co-
stimulatory signaling–induced T cell full activation (38).
We reported earlier that DOCK2 plays a crucial role in
antigen-induced TCR clustering and lipid raft clustering
(24). In addition, the present study reveals that DOCK2
also is critical for CD28-mediated Rac activation. There-
fore, it is suggested that DOCK2 deficiency impairs T cell
activation by inhibiting TCR-mediated and CD28-depen-
dent cytoskeletal reorganization.
Because tissue infiltration of activated T cells is a cru-
cial step for induction of allograft rejection, significant ef-
forts were made recently to block this process, especially
focusing on chemokine–chemokine receptor interactions
(2, 39, 40). For example, targeting of the chemokine re-
Figure 7. DOCK2 deficiency affects graft tissue infiltration of 
activated, alloreactive T cells. T cells from B6 or DOCK2 /  mice were 
cultured with mitomycin C–treated BALB/c spleen cells in the presence of 
exogenous IL-2, and adoptively transferred into RAG1 /  mice transplanted 
with BALB/c hearts. On day 6 after transfer, graft tissues were stained with 
anti-CD3  mAb (A), and the number of infiltrating T cells was analyzed in 
a semi-quantitative manner (B). Data are mean   SEM of the number of 
CD3  cells in at least six sections obtained from two mice per group. Black 
bar, B6 T cell infiltration into BALB/c heart tissues; dark gray bar, DOCK2 /  
T cell infiltration into BALB/c heart tissues. *P   0.05 comparison between 
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ceptors CXCR3, CX3CR1, or CCR1 suppressed cardiac
allograft rejection with or without cyclosporin A treat-
ment (8–10). We found that graft tissue infiltration of
DOCK2 /  T cells was impaired severely, even when al-
loreactive T cells activated in vitro were used for adoptive
transfer. These results indicate that DOCK2 deficiency
attenuates priming and activation of potentially alloreac-
tive T cells in secondary lymphoid organs, and graft tissue
infiltration of activated, alloreactive T cells.
The present study also suggests that DOCK2 defi-
ciency causes resistance to homeostatic proliferation if the
space is relatively limited. Although costimulatory mole-
cules do not play a major role in this type of T cell activa-
tion (41, 42), several lines of evidence indicate that ho-
meostatic proliferation requires the engagement of TCRs
by MHC–self-peptide complexes and cytokine/chemo-
kine stimulation, particularly IL-15 and -7 in the case of
CD8  T cells, and CCL21 for CD4  T cells (43). At this
stage, we are unable to determine the precise mechanism
by which DOCK2 deficiency affects homeostatic prolifer-
ation. However, homeostatic proliferation is considered
to be a barrier to transplantation tolerance (42, 43). In this
respect, DOCK2 deficiency might be of benefit for con-
trolling transplant rejection.
We also found that the treatment of DOCK2 /  recipi-
ent mice with a suboptimal dose (3.2 mg/kg/d) of Tac for
10 d resulted in a remarkable synergism, with almost perma-
nent engraftment of cardiac allografts. Although mononu-
clear cell infiltration and gene expression profiles were un-
changed in DOCK2 /  recipient mice, with or without Tac
treatment, the proliferative T cell response of the Tac-
treated DOCK2 /  mice was significantly lower than that of
the untreated DOCK2 /  mice on days 6 and 15 after trans-
plantation. Therefore, this effect is suggested to be caused by
the combined actions of DOCK2 deficiency, which reduces
the alloreactivity and allocytotoxicity to a “manageable”
level, and Tac treatment, which further silences the remaining
alloreactivity of T cells.
In conclusion, we have shown that DOCK2 deficiency
enables long-term survival of cardiac allografts across a com-
plete MHC mismatch by simultaneously suppressing multi-
ple and key processes that lead to allograft rejection. There-
fore, DOCK2 may be a novel therapeutic target for
controlling transplant rejection.
MATERIALS AND METHODS
Mice. B6 (H-2b), BALB/c (H-2d), and RAG1 /  B6 mice were purchased
from The Jackson Laboratory. DOCK2 /  mice have been described else-
where (23, 24). DOCK2 /  mice were backcrossed with B6 mice for more
than seven generations, and DOCK2 /  and DOCK2 /  littermates that
were obtained by intercrossing DOCK2 /  males and DOCK2 /  females
were used in this study. All animals were kept under specific pathogen-free
conditions in the animal facility at Kyushu University or Evanston Northwest-
ern Healthcare. Animals were used at 6–10 wk of age. All experiments were
done in accordance with the guidelines of the committee of Ethics on Animal
Experiment, Faculty of Medical Sciences, Kyushu University and Evanston
Northwestern Healthcare Institutional Animal Care and Use Committee.
Mouse cardiac transplantation. Vascularized cardiac allografts were
transplanted using microsurgical techniques as described by Ono and Lind-
sey (44). In brief, donor and recipient mice were anesthetized with ke-
tamine and xylazine. Donor hearts were harvested and placed in chilled
physiologic saline, during which time the recipient mice were prepared.
The donor hearts were heterotopically transplanted into recipient mice by
end-to-side anastomosis of the donor aorta and pulmonary artery to the re-
cipient’s abdominal aorta and inferior vena cava, respectively. The technical
success rate was  84%. Heart allograft survival was determined by daily pal-
pation. Rejection was considered complete at the time of cessation of a pal-
pable heart beat, and was confirmed visually after laparotomy.
Immunosuppression. Tacrolimus (Tac; an oral formulation) was sus-
pended in water and administered in a volume of 10 ml/kg/d. The
DOCK2 /  recipients were treated with Tac at a predetermined subopti-
mal dose of 3.2 mg/kg/d for 10 d beginning at transplantation.
Immunohistology and histology. Heart graft tissues were harvested
from recipients for detection of intragraft cell infiltration by immunohis-
tochemistry. 4- m frozen sections of heart tissues were cut, fixed with
acetone, and stained with primary anti–mouse antibodies against CD3 
(145-2C11), CD25 (7D4) (both obtained from BD Biosciences), and CD68
macrophage marker (FA-11) (Serotec Ltd.) at optimal dilutions. After incu-
bation, the sections were stained with peroxidase-conjugated secondary an-
tibodies, and visualized using 3-amino-9-ethylcarbazole as a chromogen.
Immunoperoxidase-stained tissue sections were evaluated semi-quantita-
tively in blinded fashion by a minimum of two of the authors. In each sec-
tion, more than six different representative fields were counted by visual
microscopy (400 ) to determine the average number of stained cells per
field of view. Average   SEM was determined from at least three separate
grafts. For morphologic analysis of heart grafts, all specimens were fixed in
10% buffered formalin and embedded in paraffin. Sections were cut and
stained with hematoxylin and eosin. Light microscopic analysis was per-
formed to assess overall cellularity and myocardial damage (45).
Quantitative real-time RT-PCR. Total RNA of heart grafts from re-
cipients was used to detect quantitatively the mRNA levels of GAPDH,
IL-2, IFN- , TNF- , RANTES, granzyme B, and perforin with the ABI
PRISM 7700 sequence detection system (Applied Biosystems). The specific
primers and probes to detect IL-2, granzyme B, and IFN-  have been de-
scribed elsewhere (46, 47). GAPDH was detected by using Taqman rodent
GAPDH control reagents (Applied Biosystems). To detect TNF- ,
RANTES, and perforin, RT-PCR was performed using the following
primers and probes: TNF- : 5 -AAGGCTGCCCCGACTATGT-3 
(sense), 5 -GCGGAGAGGAGGCTGACTT-3  (antisense), and 5 -6FAM-
CTCACCCACACCGTCAGCCGATT-TAMRA-3  (probe); RANTES:
5 -GTCGTCTTTGTCACTCGAAGGA-3  (sense), 5 -GATGTATTCT-
TGAACCCACTTCTTCTC-3  (antisense), and 5 -6FAM-CCGCCAA-
GTGTGTGCCAACCC-TAMRA-3  (probe); perforin: 5 -GCAGGT-
CAGGCCAGCATAAG-3  (sense), 5 -GCAGTCCTGGTTGGTGAC-
CTT-3  (antisense), 5 -6FAM-ATTCATGCCAGTGTGAGTGCCAG-
GATT-MGBNFQ-3  (probe). Gene expression values were normalized to
GAPDH.
T cell alloreactivity and allocytotoxicity in cardiac allografted re-
cipients. Spleens were collected from recipients for MLRs on day 6, 15,
or 30 after grafting. After T cell subpopulations were enriched with the
Mouse T Cell Recovery Column Kit (Cedarlane), T cell–enriched spleno-
cytes (2   105/well) were cultured with mitomycin C–treated splenocytes
(5   105 /well) from B6, BALB/c, or the third-party control C3H mice in
96-well round-bottom plates for 72 h. 1  Ci of 3H-thymidine was added
during the final 6 h of culture, and incorporated radioactivity was measured
with a liquid scintillation counter (Packard TRI CARB 2500). In some ex-
periments, IL-2 was added to the culture at 10 ng/ml.JEM VOL. 202, October 17, 2005 1129
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For the CTL assay, spleens were collected from recipients on day 6, 15, or
30 after grafting, and T cell–enriched splenocytes were prepared as effector cells
using the Mouse T Cell Recovery Column Kit. Target cells were prepared by
culturing BALB/c or C3H splenocytes (2.5   106/ml) with Con A (2.5  g/
ml) for 2 d. The cultures of target cells were pulsed with 2.5  Ci/ml of 3H-thy-
midine during the final 16 h. The 106/well effector cells were cultured with
104/well of 3H-thymidine–labeled target cells in 96-well round-bottom plates
for 4 h at 37 C in a humidified atmosphere of 5% CO2. The percentage of cy-
totoxicity was calculated as described in a previous protocol (48).
In vivo assessment for proliferation and infiltration of lymphocytes.
Lymphocytes were prepared from B6 and DOCK2 /  mice, and incubated
with 5  M 5,6-carboxyfluorescein diacetate succinimidyl ester (Invitrogen). La-
beled cells (60   106) were injected i.v. through the tail vein into RAG1 /  re-
cipients immediately after transplantation of B6 or BALB/c heart grafts. On day
6 after transfer, spleen and heart grafts of RAG1 /  recipient mice were har-
vested and subjected to flow cytometric or histologic analysis. In some experi-
ments, various amounts of the labeled lymphocytes were injected directly into
RAG1 /  mice and were analyzed similarly.
For transfer of activated T cells, T cell–enriched splenocytes (2   106/
ml) from B6 and DOCK2 /  mice were cultured with mitomycin
C–treated BALB/c splenocytes (8   106/ml) in the presence of IL-2 (10
ng/ml). The cells were harvested on day 4, and equal amounts of T cells
(6   106) from each group were adoptively transferred into RAG1 /  re-
cipients with BALB/c heart grafts for histologic analysis. The activation sta-
tus was confirmed by functional or flow cytometric analysis.
Pull-down assay. T cells from DOCK2 /  and DOCK2 /  mice were
incubated with anti-CD28 mAb (37.51, 5  g/ml; BD Biosciences) at 4 C
for 20 min, and stimulated with goat anti–hamster IgG Ab (G94-56, 20  g/
ml, BD Biosciences) at 37 C for the specified times. Cell extracts were in-
cubated with glutathione S-transferase (GST)–fusion, Rac binding domain
(RBD) of PAK1 at 4 C for 60 min. The GST-PAK1-RBD–bound proteins
were analyzed by SDS-PAGE, and blots were probed with the Rac-specific
mAb 23A8 (Upstate Biotechnology).
Statistical analysis. To calculate graft survival, Kaplan-Meier survival
graphs were constructed. Comparisons between groups were evaluated by
Student’s t test. Data were expressed as mean   SEM, and were considered
to be statistically significant if p-values were  0.05.
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